Table 1.
In vitro susceptibilities of E. coli DVR22 and E. coli transconjugant expressing NDM-1 carbapenemase
| Antibiotic(s) | MIC (μg/ml) in: |
||
|---|---|---|---|
| E. coli DVR22 | E. coli J53 DVR22T | E. coli J53 | |
| Amoxicillin | >256 | >256 | 4 |
| Amoxicillin + clavulanatea | 32 | 32 | 4 |
| Piperacillin + tazobactamb | >256 | >256 | 1 |
| Cefoxitin | >256 | >256 | 2 |
| Cefotaxime | >256 | >256 | 0.094 |
| Ceftazidime | >256 | >256 | 0.125 |
| Cefepime | 256 | >256 | 0.25 |
| Imipenem | 8 | 16 | 0.19 |
| Meropenem | 16 | 12 | 0.023 |
| Doripenem | 6 | 4 | 0.032 |
| Ertapenem | 24 | 18 | 0.008 |
| Aztreonam | >256 | >256 | 64 |
| Gentamicin | >8 | >8 | <1 |
| Amikacin | >32 | >32 | <4 |
| Tobramycin | >8 | >8 | <2 |
| Ciprofloxacin | >32 | 0.008 | 0.008 |
a
Clavulanate was used at a fixed concentration of 2 μg/ml.
b
Tazobactam was used at a fixed concentration of 4 μg/ml.